【Asset for Licensing】An Oral VAV1 Molecular Glue with BIC Potential

Asset: Orally bioavailable VAV1 molecular glue degrader

Development Stage: IND-enabling studies; IND dossier targeted for completion in Q1 2027

Indication: Autoimmune and inflammatory disorders

Key Asset Highlights

1. Delivers potent VAV1 protein degradation capability, robust inhibition of T-cell proliferation and multiple complementary immunomodulatory effects.
2. Demonstrates strong pharmacokinetic behavior across mice, rats and dogs. Oral systemic exposure outperforms a benchmark VAV1 degrader reference molecule.
3. Shows desirable ADME attributes including adequate solubility, moderate hepatic clearance across tested species, low potential for CYP inhibitory interactions, limited hERG liability, and negative results in the Ames mutagenicity assay.
4. Metabolite profiling using primary hepatocytes from humans, cynomolgus monkeys, dogs, rats and mice shows consistent metabolic behavior across species. No species-specific human metabolites or glutathione adducts were identified.
5. Prominent therapeutic efficacy has been validated in two representative preclinical inflammatory models: rat collagen-induced arthritis for autoimmune conditions and TNBS-triggered murine inflammatory bowel disease. Distinctly low efficacious dose ranges were achieved in both models, and the magnitude of VAV1 target degradation demonstrates a clear positive correlation with administered dose levels.
6. Modelled human pharmacokinetic parameters suggest a favorable profile: moderate clearance and steady-state volume of distribution, coupled with a relatively long half-life. Simulation predicts a low once-daily minimal effective human dose.
7. Short-term repeated oral administration at a high single tier in mice did not trigger body weight loss or overt toxic abnormalities. The projected therapeutic index sits well above 100-fold.
8. A 14-day oral dose-range-finding study was conducted in rats across multiple dose tiers. Minor histological changes in liver and spleen were only noted at the highest tested concentration in both male and female animals. The maximum tolerated dose has been defined, and the estimated therapeutic index also exceeds 100-fold.
9. The program is protected by proprietary intellectual property with confirmed freedom-to-operate; relevant patent applications have been submitted.
10. All workstreams are progressing to finalize the full IND-enabling package, on track for completion in Q1 2027.